Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04196140 · ClinicalTrials.gov registry record · NA
Pivotal Omnipod Horizon™ Automated Glucose Control System
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
NCT04196140: Completed NA study, sponsored by Insulet Corporation.
NCT04196140 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 240 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04196140, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
Study Summary
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting and an optional 12-month extension phase.
Primary Outcome
Measure of serious device-related adverse events
Interventions
- DEVICE Omnipod Horizon™ Automated Glucose Control System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2019-12-30 |
| Est. Completion | 2022-04-20 |
| Phase | NA |
What the finished NCT04196140 record still lists
NCT04196140 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Omnipod Horizon™ Automated Glucose Control System is the first listed.
NCT04196140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04196140 about?
NCT04196140 is a clinical study titled "Pivotal Omnipod Horizon™ Automated Glucose Control System". Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting and an optional 12-month extension phase.
What is the current status of trial NCT04196140?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2019-12-30. Estimated completion is 2022-04-20.
What interventions are being tested in trial NCT04196140?
The interventions under investigation include: Omnipod Horizon™ Automated Glucose Control System (DEVICE).
Who is sponsoring clinical trial NCT04196140?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04196140's enrollment target sits among peer trials
240 440th of 2000 higher than 1,542 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI